Related articles

• Randomized Controlled Trial

  Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study.

  Int. J. Cardiol. 2014 Mar 15;172(2):411-8.

• Multicenter Study

  Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial.

  Emerg Med J. 2013 Aug 1;30(8):633-7.

• Multicenter Study

  Pro-adrenomedullin, pro-endothelin-1, procalcitonin, C-reactive protein and mortality risk in critically ill children: a prospective study.

  Crit Care. 2013 Jan 1;17(5):R240.

Show more related articles...